目的:研究淋巴瘤细胞胞外体(lymphoma cell-derived exosomes,LCEX)的生物学特性及其在抗肿瘤免疫中的作用,探讨以胞外体为基础的肿瘤免疫治疗的可行性。方法:本研究以Raji细胞株为淋巴瘤细胞模型,应用免疫电镜,Westernblot,共聚焦显微镜以及细胞毒杀伤实验等技术对其释放的LCEX的生物特性进行初步研究。结果:淋巴瘤细胞同样也能释放胞外体,与其他肿瘤细胞相似,LCEX同样负载重要的免疫分子HSP70及ICAM-1分子。同时,LCEX能够在体外靶向结合树突状细胞(dendriticcell,DC),并能诱导抗原特异性的抗淋巴瘤效应。结论:淋巴瘤细胞同样能够释放胞外体,LCEX负载有淋巴瘤细胞的相关蛋白分子,有望成为淋巴瘤细胞抗原的重要来源之一,体外致敏DC能够诱导抗淋巴瘤免疫,在淋巴瘤免疫治疗方面具有广阔的应用前景。
Objective To investigate the biological properties and effects of anti-lymphoma of lymphoma cell-derived exosomes(LCEX),and feasibility of LCEX-based immunotherapy.Methods Raji cell line was used as cell model,and its morphology,protein expression,and effects of anti-lymphoma were examined with electronic microscope,western blotting,conforcal and cytotoxicity assay.Results Our data showed that same as other tumor cells,lymphoma cell can also release exosomes,and LCEX harbor some molecules expressed on lymphoma cells and also express important immune molecules such as HSP70,LCEX can induce anti-lymphoma CTL response.Conclutions our data indicated that LCEX could target dendritic cells in vitro,and LCEX targeted dendritic cells can induce more stronger anti-lymphoma CTL response,thus our study suggested that lymphoma cell-derived exosome may represent a more effective exosome-based vaccine in induction of anti-lymphoma immunity.